Oxford Biomedica PLC Director/PDMR Shareholding (1724K)

TIDMOXB

RNS Number : 1724K

Oxford Biomedica PLC

03 May 2022

PDMR Dealings

Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share. Following this transaction Dr. Jason Slingsby continues to hold 120,476 options over ordinary shares.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Jason Slingsby 
     -----------------------------  --------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position/status                Chief Business & Corporate Development 
                                      Officer 
     -----------------------------  --------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  --------------------------------------- 
 3.   Details of the Issuer 
     ---------------------------------------------------------------------- 
 a)   Name                           Oxford BioMedica plc 
     -----------------------------  --------------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  --------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of                 Options over ordinary Shares of 50 
       the financial                  pence each 
       instrument                     ISIN: GB00BDFBVT43 
       Identification 
       code 
     -----------------------------  --------------------------------------- 
 b)   Nature of the                  Exercise of options at nil cost 
       transaction 
     -----------------------------  --------------------------------------- 
 c)   Currency                       GBP - British pound 
     -----------------------------  --------------------------------------- 
 d)   Price(s) and volumes(s)          Price(s)    Volume(s) 
                                        Nil         8,712 
                                                   ---------- 
     -----------------------------  --------------------------------------- 
 e)        Aggregated information     8,712 
             *    Aggregate volume     Nil 
                                       Nil 
 
 
             *    Price 
 
 
 
             *    Aggregated total 
     -----------------------------  --------------------------------------- 
 f)   Date of the transaction        2022-04-27 
     -----------------------------  --------------------------------------- 
 g)   Place of the transaction       Outside a trading venue 
     -----------------------------  --------------------------------------- 
 
 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Jason Slingsby 
     -----------------------------  --------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position/status                Chief Business & Corporate Development 
                                      Officer 
     -----------------------------  --------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  --------------------------------------- 
 3.   Details of the Issuer 
     ---------------------------------------------------------------------- 
 a)   Name                           Oxford BioMedica plc 
     -----------------------------  --------------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  --------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of                 Ordinary Shares of 50 pence each 
       the financial                  ISIN: GB00BDFBVT43 
       instrument 
       Identification 
       code 
     -----------------------------  --------------------------------------- 
 b)   Nature of the                  Disposal 
       transaction 
     -----------------------------  --------------------------------------- 
 c)   Currency                       GBP - British pound 
     -----------------------------  --------------------------------------- 
 d)   Price(s) and volumes(s)          Price(s)    Volume(s) 
                                        GBP5.39     8,712 
                                                   ---------- 
     -----------------------------  --------------------------------------- 
 e)        Aggregated information     8,712 
             *    Aggregate volume     GBP5.39 
                                       GBP46,957.68 
 
 
             *    Price 
 
 
 
             *    Aggregated total 
     -----------------------------  --------------------------------------- 
 f)   Date of the transaction        2022-04-27 
     -----------------------------  --------------------------------------- 
 g)   Place of the transaction       London Stock Exchange, Main Market 
                                      (XLON) 
     -----------------------------  --------------------------------------- 
 

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUGDUDSGDGDX

(END) Dow Jones Newswires

May 03, 2022 11:46 ET (15:46 GMT)